Brevan Howard Capital Management LP Allogene Therapeutics, Inc. Transaction History
Brevan Howard Capital Management LP
- $12.7 Billion
- Q1 2024
A detailed history of Brevan Howard Capital Management LP transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 32,186 shares of ALLO stock, worth $68,234. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,186
Previous 98,120
67.2%
Holding current value
$68,234
Previous $314,000
54.46%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding ALLO
# of Institutions
164Shares Held
106MCall Options Held
97.5KPut Options Held
45.6K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$39.7 Million1.76% of portfolio
-
Black Rock Inc. New York, NY9.65MShares$20.5 Million0.0% of portfolio
-
State Street Corp Boston, MA9.18MShares$19.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.21MShares$17.4 Million0.0% of portfolio
-
Primecap Management CO Pasadena, CA5.45MShares$11.6 Million0.02% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $305M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...